ATE370958T1 - Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung - Google Patents

Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung

Info

Publication number
ATE370958T1
ATE370958T1 AT03782672T AT03782672T ATE370958T1 AT E370958 T1 ATE370958 T1 AT E370958T1 AT 03782672 T AT03782672 T AT 03782672T AT 03782672 T AT03782672 T AT 03782672T AT E370958 T1 ATE370958 T1 AT E370958T1
Authority
AT
Austria
Prior art keywords
phosphonooxy
pharmaceutical use
quinazoline derivatives
quinazoline
derivatives
Prior art date
Application number
AT03782672T
Other languages
English (en)
Inventor
Nicola Murdoch Heron
Frederic Henri Jung
Georges Rene Pasquet
Andrew A Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE370958T1 publication Critical patent/ATE370958T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03782672T 2002-12-24 2003-12-22 Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung ATE370958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293238 2002-12-24
EP03291315 2003-06-02

Publications (1)

Publication Number Publication Date
ATE370958T1 true ATE370958T1 (de) 2007-09-15

Family

ID=32683824

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07009390T ATE438644T1 (de) 2002-12-24 2003-12-22 Chinazolinderivate
AT03782672T ATE370958T1 (de) 2002-12-24 2003-12-22 Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07009390T ATE438644T1 (de) 2002-12-24 2003-12-22 Chinazolinderivate

Country Status (30)

Country Link
US (4) US7528121B2 (de)
EP (2) EP1847539B1 (de)
JP (3) JP4422102B2 (de)
KR (1) KR101010299B1 (de)
AR (2) AR042668A1 (de)
AT (2) ATE438644T1 (de)
AU (1) AU2003290313B2 (de)
BR (1) BRPI0317717B8 (de)
CA (1) CA2511613C (de)
CL (1) CL2003002731A1 (de)
CY (2) CY1107775T1 (de)
DE (2) DE60328735D1 (de)
DK (2) DK1847539T3 (de)
ES (2) ES2329623T3 (de)
HK (2) HK1080481A1 (de)
IL (2) IL169112A (de)
IS (2) IS2504B (de)
MX (1) MXPA05006918A (de)
MY (2) MY136174A (de)
NO (2) NO335193B1 (de)
NZ (1) NZ540698A (de)
PL (2) PL223998B1 (de)
PT (2) PT1578755E (de)
RU (3) RU2357971C2 (de)
SA (1) SA04240504B1 (de)
SI (2) SI1578755T1 (de)
TW (2) TWI336327B (de)
UA (1) UA83814C2 (de)
UY (1) UY28149A1 (de)
WO (1) WO2004058781A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL211694B1 (pl) * 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
KR20050087863A (ko) * 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
MXPA05011076A (es) * 2003-04-16 2006-01-24 Astrazeneca Ab Derivados de quinazolina para el tratamiento de cancer.
JP4939220B2 (ja) * 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
JP4237242B2 (ja) * 2004-10-12 2009-03-11 アストラゼネカ アクチボラグ キナゾリン誘導体
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
EP1812439B2 (de) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinaseinhibitoren
US8178672B2 (en) * 2004-10-19 2012-05-15 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US7501430B2 (en) * 2006-04-17 2009-03-10 Arqule, Inc. RAF inhibitors and their uses
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609619D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Combination
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
US20110136766A1 (en) * 2008-03-04 2011-06-09 Vitae Pharmaceuticals, Inc. Aurora kinase inhibitors
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
WO2009134658A2 (en) 2008-04-30 2009-11-05 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
WO2010002779A2 (en) * 2008-07-03 2010-01-07 Merck Serono S.A. Naphthyridininones as aurora kinase inhibitors
MX2011005788A (es) * 2008-12-05 2011-06-21 Arqule Inc Inhibidores raf y sus usos.
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
KR101849059B1 (ko) 2008-12-11 2018-04-13 악센투아 파마슈투칼스 아베 제니스테인의 결정성 형태
CA2747326C (en) 2008-12-22 2017-05-16 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
WO2012122011A2 (en) 2011-03-04 2012-09-13 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TWI592417B (zh) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 胺基喹唑啉激酶抑制劑之前藥
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR102277833B1 (ko) 2013-02-20 2021-07-14 칼라 파마슈티컬스, 인크. 치료 화합물 및 그의 용도
CA2902132C (en) * 2013-02-21 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Quinazolines as kinase inhibitors
CA2922279C (en) * 2013-09-16 2022-08-16 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
US20180207173A1 (en) 2015-07-21 2018-07-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
BR112019004463A2 (pt) 2016-09-08 2019-05-28 Kala Pharmaceuticals Inc formas cristalinas de compostos terapêuticos, seus processos de obtenção e seus métodos de uso
CN117883449A (zh) 2017-09-08 2024-04-16 里兰斯坦福初级大学理事会 Enpp1抑制剂以及它们用于治疗癌症的用途
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2021094379A1 (en) 2019-11-12 2021-05-20 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN112939948B (zh) * 2019-12-11 2022-05-17 苏州美诺医药科技有限公司 新型含喹唑啉类化合物及其中间体与应用
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
CA2102780C (en) 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (de) 1994-11-12 1997-12-01 Zeneca Ltd
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ATE315654T1 (de) 1995-12-18 2006-02-15 Sugen Inc Diagnose und behandlung von mit aur-1 und/oder aur-2 assoziierten erkrankungen
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT880508E (pt) 1996-02-13 2003-07-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
AU756556B2 (en) * 1998-10-08 2003-01-16 Astrazeneca Ab Quinazoline derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
WO2001021596A1 (en) 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
SK18102002A3 (sk) 2000-06-28 2003-07-01 Astrazeneca Ab Substituované chinazolínové deriváty, ich použitie a kompozícia obsahujúca tieto deriváty
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
SK52003A3 (en) 2000-07-07 2003-07-01 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
AU2002350105A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
GB0124299D0 (en) * 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
PL211694B1 (pl) * 2001-12-24 2012-06-29 Astrazeneca Ab Podstawiona pochodna chinazoliny, jej zastosowania oraz jej kompozycja farmaceutyczna
MY136174A (en) * 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
KR20050087863A (ko) * 2002-12-24 2005-08-31 아스트라제네카 아베 퀴나졸린 화합물
MXPA05011076A (es) * 2003-04-16 2006-01-24 Astrazeneca Ab Derivados de quinazolina para el tratamiento de cancer.

Also Published As

Publication number Publication date
BRPI0317717B8 (pt) 2021-05-25
US20060116357A1 (en) 2006-06-01
HK1111417A1 (en) 2008-08-08
MY136174A (en) 2008-08-29
AR042668A1 (es) 2005-06-29
AR057753A2 (es) 2007-12-19
DE60315892D1 (de) 2007-10-04
PL223998B1 (pl) 2016-11-30
MXPA05006918A (es) 2005-08-18
NO335446B1 (no) 2014-12-15
US7528121B2 (en) 2009-05-05
WO2004058781A1 (en) 2004-07-15
AU2003290313B2 (en) 2007-05-10
RU2357971C2 (ru) 2009-06-10
EP1578755B1 (de) 2007-08-22
IS2504B (is) 2009-04-15
NO335193B1 (no) 2014-10-20
US20150307534A1 (en) 2015-10-29
TW200510342A (en) 2005-03-16
DE60315892T2 (de) 2008-08-14
US9018191B2 (en) 2015-04-28
UY28149A1 (es) 2004-07-30
SI1578755T1 (sl) 2007-12-31
KR101010299B1 (ko) 2011-01-25
KR20050088333A (ko) 2005-09-05
JP4422102B2 (ja) 2010-02-24
NZ540698A (en) 2008-05-30
PT1578755E (pt) 2007-10-19
ATE438644T1 (de) 2009-08-15
US20140162984A1 (en) 2014-06-12
AU2003290313A1 (en) 2004-07-22
RU2007121850A (ru) 2008-12-20
PL412704A1 (pl) 2015-10-12
TW201102369A (en) 2011-01-16
IL169112A (en) 2010-12-30
EP1578755A1 (de) 2005-09-28
US8268841B2 (en) 2012-09-18
PL221490B1 (pl) 2016-04-29
IS2884B (is) 2014-06-15
DK1578755T3 (da) 2007-11-12
IS7948A (is) 2005-07-20
PT1847539E (pt) 2009-10-06
TWI393710B (zh) 2013-04-21
SA04240504A (ar) 2005-12-03
UA83814C2 (ru) 2008-08-26
US20100069412A1 (en) 2010-03-18
CL2003002731A1 (es) 2005-01-07
TWI336327B (en) 2011-01-21
PL377680A1 (pl) 2006-02-06
HK1080481A1 (en) 2006-04-28
DE60328735D1 (de) 2009-09-17
RU2005123485A (ru) 2006-03-10
MY147761A (en) 2013-01-31
US9567358B2 (en) 2017-02-14
SI1847539T1 (sl) 2010-01-29
NO20131444L (no) 2005-08-03
JP2009046514A (ja) 2009-03-05
IL185176A (en) 2011-10-31
RU2350611C1 (ru) 2009-03-27
IS8714A (is) 2008-02-13
EP1847539A1 (de) 2007-10-24
JP4503090B2 (ja) 2010-07-14
ES2290529T3 (es) 2008-02-16
IL169112A0 (en) 2009-02-11
CY1109479T1 (el) 2014-08-13
SA04240504B1 (ar) 2008-04-01
JP2006512418A (ja) 2006-04-13
CY1107775T1 (el) 2013-06-19
CA2511613A1 (en) 2004-07-15
BRPI0317717B1 (pt) 2017-12-19
CA2511613C (en) 2012-10-02
NO20052855D0 (no) 2005-06-13
IL185176A0 (en) 2007-12-03
JP2007326862A (ja) 2007-12-20
BR0317717A (pt) 2005-11-22
EP1847539B1 (de) 2009-08-05
DK1847539T3 (da) 2009-11-09
ES2329623T3 (es) 2009-11-27
JP4906608B2 (ja) 2012-03-28
NO20052855L (no) 2005-08-03

Similar Documents

Publication Publication Date Title
DE60315892D1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
DE60314600D1 (de) O-cyclopropyl-carboxanilide und ihre verwendung als fungizide
DE602005014236D1 (de) N-hydroxyamid derivate und ihre verwendung
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ATE502035T1 (de) 2-amido-4-phenylthiazol-derivate, ihre herstellung und ihre therapeutische verwendung
ATE459608T1 (de) Oxopiperidinderivate, ihre herstellung und therapeutische verwendung
DE60323754D1 (de) Dioxan-2-alkylkarbamaten derivaten, deren herstellung und deren therapeutischen verwendung
IL172087A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE60321372D1 (de) 3-phenylpyridoindolderivate, ihre herstellung und verwendung
DE60311598D1 (de) Naphthyridin-derivate und ihre verwendung als fungizide
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
ZA200504997B (en) Phosphonooxy quinazolin derivatives and their pharmaceutical use
DE60238856D1 (de) Anthranilsäureamide und ihre pharmazeutische verwendung
DE50313185D1 (de) 2-pyrrolidin-2-yl-ä1,3,4ü -oxadiazol-derivate und ihre verwendung als antidepressiva
DE60316134D1 (de) Substituierte aminoisoxazolinderivate und ihre verwendung als antidepressiva
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
ATE362916T1 (de) Substituierte propan- 1,3-diamin-derivate und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1578755

Country of ref document: EP